RecruitingPhase 2Drug trialBortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyThis is a single-arm, open-label phase II study with a safety lead-in phase.